Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 9/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 8/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634482 | 0.67 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9697990 | 0.63 | — | — | |
| SCHEMBL13139296 | 0.59 | — | — | |
| SCHEMBL1415013 | 0.56 | KDM4E (0.30) | KDM4E | |
| SCHEMBL971225 | 0.56 | — | — | |
| SCHEMBL1621735 | 0.56 | — | — | |
| SCHEMBL17808767 | 0.55 | — | — | |
| SCHEMBL11830833 | 0.54 | — | — | |
| SCHEMBL819464 | 0.52 | — | — | |
| SCHEMBL12361763 | 0.50 | ALOX15 (0.41) | ALDH1A1ALOX15HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196546-A1 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY | 2015-07-16 | — | — | US | claimed |
| EP-2887940-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | Cornell University (US) | 2015-07-01 | — | — | EP | claimed |
| WO-2014031759-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-02-27 | — | — | WO | claimed |
| EP-3224263-B1 | USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 | BIOXCEL LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-10617683-B2 | Inhibitors of CRL4 ubiquitin ligase and uses thereof | CORNELL UNIVERSITY (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617683-B2 | Inhibitors of CRL4 ubiquitin ligase and uses thereof | CORNELL UNIVERSITY (US) | 2020-04-14 | — | — | US | disclosed |
| US-10610563-B2 | Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2 | BIOXCEL CORPORATION (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170360872-A1 | USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 | BIOXCEL CORPORATION (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3224263-A1 | USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 | Bioxcel Corporation (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016085943-A1 | USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 | RASTELLI, LUCA (US) | 2016-06-02 | — | — | WO | disclosed |
| CN-104968323-A | Inhibitors of CRL4 ubiquitin ligase and uses thereof | UNIV CORNELL | 2015-10-07 | — | — | CN | disclosed |
| US-20150196546-A1 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| EP-2887940-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | Cornell University (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887940-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | Cornell University (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031759-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031759-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-02-27 | — | — | WO | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 534/4885ALOX15 722/4885HSD17B10 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.